Amgen identifies promising KRAS combination for colorectal cancer

Data emerging from ESMO suggest Amgen may have hit on an effective pairing for its first-in-class KRAS inhibitor in a new indication, colorectal cancer, on its first attempt. 

In an abstract presented at the European Society of Medical Oncology meeting on Thursday, the company reported its KRAS inhibitor Lumakras sotorasib plus anti-EGFR mAb Vectibix panitumumab led to an overall response rate of 26.9%, including unconfirmed partial responses, in 26 metastatic colorectal cancer patients expressing the KRAS G12C mutation and treated with a median of two prior therapies in the Phase Ib/II CodeBreak101 study...